Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2023 | 374 | 5.190 |
Why?
|
| Mastectomy | 15 | 2023 | 34 | 3.270 |
Why?
|
| Surgeons | 8 | 2023 | 82 | 2.580 |
Why?
|
| Organ Sparing Treatments | 2 | 2020 | 11 | 1.290 |
Why?
|
| Mastectomy, Segmental | 8 | 2023 | 29 | 1.240 |
Why?
|
| Nipples | 4 | 2021 | 5 | 1.190 |
Why?
|
| Ergonomics | 3 | 2021 | 6 | 1.000 |
Why?
|
| Mammaplasty | 3 | 2023 | 6 | 0.940 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2021 | 1 | 0.730 |
Why?
|
| Mammography | 1 | 2019 | 43 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 99 | 0.570 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 2 | 0.570 |
Why?
|
| Rare Diseases | 1 | 2017 | 10 | 0.560 |
Why?
|
| Female | 25 | 2023 | 14048 | 0.560 |
Why?
|
| Quality of Life | 2 | 2019 | 541 | 0.470 |
Why?
|
| Humans | 27 | 2023 | 24703 | 0.470 |
Why?
|
| Middle Aged | 13 | 2023 | 8294 | 0.300 |
Why?
|
| Surgical Oncology | 2 | 2019 | 6 | 0.300 |
Why?
|
| Pilot Projects | 2 | 2019 | 370 | 0.290 |
Why?
|
| Prospective Studies | 3 | 2021 | 1612 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 244 | 0.270 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 332 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 30 | 0.230 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 23 | 0.230 |
Why?
|
| Prognosis | 4 | 2019 | 674 | 0.230 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 51 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 11 | 0.200 |
Why?
|
| Breast Implants | 2 | 2019 | 5 | 0.200 |
Why?
|
| Breast Neoplasms, Male | 1 | 2022 | 11 | 0.190 |
Why?
|
| Societies, Medical | 2 | 2019 | 118 | 0.180 |
Why?
|
| Operating Rooms | 1 | 2021 | 13 | 0.180 |
Why?
|
| Workload | 1 | 2021 | 23 | 0.180 |
Why?
|
| Adult | 8 | 2023 | 7255 | 0.180 |
Why?
|
| Oncologists | 1 | 2021 | 2 | 0.180 |
Why?
|
| Burnout, Professional | 1 | 2021 | 23 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 31 | 0.170 |
Why?
|
| Contraindications, Procedure | 1 | 2020 | 4 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1671 | 0.170 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 22 | 0.160 |
Why?
|
| Medical Overuse | 1 | 2019 | 6 | 0.160 |
Why?
|
| Acellular Dermis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 44 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2019 | 3 | 0.160 |
Why?
|
| Radiologists | 1 | 2019 | 7 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 53 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2019 | 24 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 44 | 0.150 |
Why?
|
| Intraoperative Care | 1 | 2019 | 38 | 0.150 |
Why?
|
| Radiation Oncology | 1 | 2019 | 14 | 0.150 |
Why?
|
| Operative Time | 1 | 2019 | 77 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 118 | 0.150 |
Why?
|
| Stromal Cells | 1 | 2018 | 33 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 198 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 192 | 0.140 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 5 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 182 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 211 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 28 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 113 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 83 | 0.120 |
Why?
|
| Aged | 8 | 2023 | 8382 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 39 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 53 | 0.120 |
Why?
|
| Neoplasms | 1 | 2017 | 213 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 48 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2017 | 212 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 134 | 0.110 |
Why?
|
| Pain | 1 | 2017 | 382 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2019 | 3156 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 162 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 1042 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 807 | 0.100 |
Why?
|
| Young Adult | 3 | 2023 | 1847 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 536 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2016 | 864 | 0.080 |
Why?
|
| Rosaniline Dyes | 1 | 2008 | 2 | 0.080 |
Why?
|
| Radioisotopes | 1 | 2008 | 13 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 85 | 0.070 |
Why?
|
| Adolescent | 2 | 2023 | 1992 | 0.070 |
Why?
|
| United States | 2 | 2021 | 1873 | 0.060 |
Why?
|
| Time Factors | 2 | 2019 | 1327 | 0.050 |
Why?
|
| Self Concept | 1 | 2023 | 38 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2023 | 54 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2019 | 532 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2023 | 137 | 0.050 |
Why?
|
| Emotions | 1 | 2021 | 72 | 0.040 |
Why?
|
| Male | 3 | 2022 | 13669 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 135 | 0.040 |
Why?
|
| Video Recording | 1 | 2019 | 31 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 1748 | 0.040 |
Why?
|
| Body Image | 1 | 2019 | 20 | 0.040 |
Why?
|
| Fear | 1 | 2019 | 43 | 0.040 |
Why?
|
| Esthetics | 1 | 2019 | 11 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 62 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 40 | 0.040 |
Why?
|
| Patient Preference | 1 | 2019 | 32 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 2019 | 21 | 0.040 |
Why?
|
| Pectoralis Muscles | 1 | 2019 | 18 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 82 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2019 | 48 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 128 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 86 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2019 | 131 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 183 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 284 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 62 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 4509 | 0.040 |
Why?
|
| Wound Healing | 1 | 2019 | 151 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 315 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 279 | 0.030 |
Why?
|
| Needles | 1 | 2016 | 17 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 443 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2018 | 198 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 499 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1293 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 476 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 728 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 278 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1026 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 362 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 6 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2008 | 13 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 125 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 243 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3208 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 234 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 437 | 0.020 |
Why?
|